"Protein Structure." . . "Protein Structure" . "Post-translational modification." . . "Enzyminhibitor" . . "Phosphodiesterasen." . . "Phosphodiesterasen" . "Cell Physiology." . . "Cell physiology." . "Pharmaceutical chemistry." . . "Médicaments Ciblage." . . "Cytology." . . "Phosphodiesterase Inhibitors therapeutic use." . . "Phosphodiesterasehemmer." . . "Science." . . "Pharmacology/Toxicology." . . "Pharmacology/Toxicology" . . . "Phosphoric Diester Hydrolases therapeutic use." . . "Phosphodiestérases." . . "Phosphodiesterases." . "Medicinal Chemistry." . . "Enzymology." . . "Pharmakotherapie." . . "Arzneimitteldesign." . . "Phosphoric Diester Hydrolases pharmacology." . . "Posttranslational Modification." . . "Natural history." . . "Enzymes." . . "Biomedicine." . . "Biomedicine" . "Post-translational modification of proteins." . . "Post-translational modification of proteins" . "Toxicology." . . "Drug targeting." . . "Drug Discovery." . . "Pharmakologie." . . "Découverte de médicament." . . "Medicine." . . "Inhibiteurs de la phosphodiestérase." . . "Phosphodiesterase Inhibitors pharmacology." . . "Cyclic nucleotide phosphodiesterases (PDEs) are promising targets for pharmacological intervention. Multiple PDE genes, isoform diversity, selective expression and compartmentation of the isoforms, and an array of conformations of PDE proteins are properties that challenge development of drugs that selectively target this class of enzymes. Novel characteristics of PDEs are viewed as unique opportunities to increase specificity and selectivity when designing novel compounds for certain therapeutic indications. This chapter provides a summary of the major concepts related to the design and use of PDE inhibitors." . . . . . . . . . . . . . . . . . . . . . . . . . . . "Phosphodiesterases as Drug Targets"@en . "Phosphodiesterases as Drug Targets" . . . . . . "Phosphodiesterases as drug targets" . "Phosphodiesterases as drug targets"@en . . . . . . . . . . "Electronic books"@en . "Electronic books" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Aufsatzsammlung" . . . "Cyclic nucleotide phosphodiesterases (PDEs) are promising targets for pharmacological intervention. Multiple PDE genes, isoform diversity, selective expression and compartmentation of the isoforms, and an array of conformations of PDE proteins are properties that challenge development of drugs that selectively target this class of enzymes. Novel characteristics of PDEs are viewed as unique opportunities to increase specificity and selectivity when designing novel compounds for certain therapeutic indications. This chapter provides a summary of the major concepts related to the design and use o."@en . . "Cyclic nucleotide phosphodiesterases (PDEs) are promising targets for pharmacological intervention. Multiple PDE genes, isoform diversity, selective expression and compartmentation of the isoforms, and an array of conformations of PDE proteins are properties that challenge development of drugs that selectively target this class of enzymes. Novel characteristics of PDEs are viewed as unique opportunities to increase specificity and selectivity when designing novel compounds for certain therapeutic indications. This chapter provides a summary of the major concepts related to the design and use of PDE inhibitors."@en . "Biochemistry." . . "Pharmacie Innovations." . . "Arzneistoffträger" . .